Sugi Predict

Sugi Predict / Compounds / SCHEMBL754826

SCHEMBL754826

SCHEMBL754826

CCOC(=O)c1ccc(N)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.62
▸ MAOA P21397 2/20 0.62
▸ CYP1A2 P05177 2/20 0.62
▸ CYP3A4 P08684 1/20 0.62
▸ ADRB2 P07550 1/20 0.57
▸ ADRB1 P08588 1/20 0.57
▸ ADRB3 P13945 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.54
▸ HSD17B10 Q99714 3/20 0.54
▸ GAA P10253 4/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ MAPT P10636 2/20 0.54
▸ ALOX15 P16050 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ TSHR P16473 2/20 0.53
▸ CA12 O43570 4/20 0.53
▸ CA1 P00915 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2888716 0.87 TSHR (0.60) LMNAMAOACYP1A2CYP3A4ALDH1A1
SCHEMBL29375324 0.86 ALDH1A1 (0.64) LMNAMAOACYP1A2CYP3A4ALDH1A1
SCHEMBL549053 0.86 LMNA (0.58) LMNAMAOACYP1A2CYP3A4ADRB2
SCHEMBL2132644 0.86 ALDH1A1 (0.64) LMNAMAOACYP1A2CYP3A4ALDH1A1
SCHEMBL12393858 0.85 TSHR (0.65) LMNAMAOACYP1A2CYP3A4ADRB2
Hydrochloric Acid SCHEMBL28654606 0.84 LMNA (0.49) LMNAMAOACYP1A2CYP3A4ADRB2
Hydrochloric Acid SCHEMBL3178327 0.84 LMNA (0.56) LMNAMAOACYP1A2CYP3A4ADRB2
SCHEMBL11784914 0.84 LMNA (0.56) LMNAMAOACYP1A2CYP3A4ADRB2
SCHEMBL1480079 0.84 CA12 (0.70) LMNAMAOACYP1A2CYP3A4ALDH1A1
SCHEMBL751617 0.83 LMNA (0.54) LMNAMAOACYP1A2CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116730657-B Cold patch asphalt mixture and preparation method thereof 芜湖城瑞路桥建设有限公司 2024-07-12 — — CN claimed
CN-116730657-A Cold patch asphalt mixture and preparation method thereof 芜湖城瑞路桥建设有限公司 2023-09-12 — — CN claimed
CN-102690211-B The preparation method of tolvaptan intermediate ZHENGZHOU MINGZE MEDICAL TECHNOLOGY CO.,LTD. (CN) 2015-12-09 — — CN claimed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
CN-116730657-B Cold patch asphalt mixture and preparation method thereof 芜湖城瑞路桥建设有限公司 2024-07-12 — — CN disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed
CN-116730657-A Cold patch asphalt mixture and preparation method thereof 芜湖城瑞路桥建设有限公司 2023-09-12 — — CN disclosed
EP-2565182-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2017-10-11 — — EP disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 — — US disclosed
US-20100130484-A1 NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS ACKERMANN JEAN 2010-05-27 — — US disclosed
US-7696200-B2 Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2010-04-13 — — US disclosed
EP-1996563-A1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2008-12-03 — — EP disclosed
WO-2007093507-A1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 — — WO disclosed
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-16 — — US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 — — US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 — — EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130484-A1 NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 LMNA 3212/4885MAOA 2525/4885CYP1A2 357/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 LMNA 2984/4885MAOA 2511/4885CYP1A2 742/4885
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 LMNA 4540/4885MAOA 4268/4885CYP1A2 3280/4885
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors CPT1A, CPT1B, CPT2 LMNA 3212/4885MAOA 2525/4885CYP1A2 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.